文献速递糖尿病

1型糖尿病的异质性:对发病机制、预防和治疗的启示——2024年《糖尿病》《糖尿病护理》与《糖尿病学》专家论坛

The Heterogeneity of Type 1 Diabetes: Implications for Pathogenesis, Prevention, and Treatment-2024 Diabetes, Diabetes Care, and Diabetologia Expert Forum.
PubMed 文献 · Diabetes Care · 2025-01-01

本文总结2024年6月由《糖尿病》《糖尿病护理》与《糖尿病学》编辑组织的国际专家论坛对1型糖尿病异质性的当前认识。论坛回顾了影响1型糖尿病发生和进展的关键因素,提出了高优先级研究问题,并概述了利用疾病异质性开发个体化治疗的机会。

要点

  • 遗传风险、免疫与代谢表型共同影响并刻画1型糖尿病的进展。
  • 年龄相关因素沿梯度决定疾病侵袭性,免疫遗传通路聚集成网络影响β细胞。
  • 异质性为预防和干预开辟途径,包括疾病修饰免疫治疗和胰岛细胞替代。

核心结论

  • 论坛呼吁继续研究以识别更多整体和特定亚组中贡献疾病的因素。
  • 呼吁研究聚焦于超越代谢和免疫阈值并发生糖尿病者与同等免疫遗传风险但保持无病者。
  • 呼吁识别当前1型糖尿病分期系统的不足并改进以在预防和干预策略中捕获和利用异质性。

研究设计与样本

  • 本文为2024年6月由《糖尿病》《糖尿病护理》与《糖尿病学》编辑组织的国际专家论坛的总结。

主要发现

  • 遗传风险、免疫和代谢表型影响并刻画1型糖尿病进展,以风险因素调色板形式呈现。
  • 年龄相关因素沿梯度决定疾病侵袭性。
  • 可变免疫遗传通路聚集成网络影响β细胞和其他胰腺病理,导致不同年龄和不同严重程度的临床疾病,以疾病相关阈值描述。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This article summarizes the current understanding of the heterogeneity of type 1 diabetes from a June 2024 international Expert Forum organized by the editors of Diabetes, Diabetes Care, and Diabetologia. The Forum reviewed key factors contributing to the development and progression of type 1 diabetes and outlined specific, high-priority research questions. Knowledge gaps were identified, and, notably, opportunities to harness disease heterogeneity to develop personalized therapies were outlined. Herein, we summarize our discussions and review the heterogeneity of genetic risk and immunologic and metabolic phenotypes that influence and characterize type 1 diabetes progression (presented as a palette of risk factors). We discuss how these age-related factors determine disease aggressiveness (along gradients) and describe how variable immunogenetic pathways aggregate (into networks) to affect β-cell and other pancreatic pathologies to cause clinical disease at different ages and with variable severity (described as disease-related thresholds). Heterogeneity of pathogenesis and clinical severity opens avenues to prevention and intervention, including the potential of disease-modifying immunotherapy and islet cell replacement. We conclude with a call for 1) continued research to identify more factors contributing to the disease, both overall and in specific subgroups; 2) investigations focusing on both individuals who surpass metabolic and immune thresholds and develop diabetes and those who remain disease free with the same level of immunogenetic risk; and 3) efforts to identify where the current type 1 diabetes staging system may fall short and determine how it can be improved to capture and leverage heterogeneity in prevention and intervention strategies.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Evans-Molina C, Dor Y, Lernmark Å, et al. The Heterogeneity of Type 1 Diabetes: Implications for Pathogenesis, Prevention, and Treatment-2024 Diabetes, Diabetes Care, and Diabetologia Expert Forum. Diabetes Care. 2025. PMID: 40736378. doi:10.2337/dci25-0013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。